The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus

Summary

Type 2 diabetes (T2D) is a major risk factor of chronic heart failure (CHF). Glycemic control in patients with the combination of T2D and CHF is complicated and the currently available treatments have proven to be inadequate in clinical trials. Objectives To investigate the effect of Liraglutide compared to placebo on left ventricular ejection fraction (LVEF) in CHF patients with and without T2D. Multicenter, randomized, double blind study of 240 patients with documented systolic CHF (50% with T2DM) will be randomised. The effect of Liraglutide on left ventricular systolic and diastolic function will be evaluated by advanced echocardiography Primary outcome parameter is change in LVEF from visit 1 to week 24.

Timeline

Start

2011-11

Primary completion

2015-09

Completion

2015-10

Publications

• Nielsen R, Jorsal A, Iversen P, Tolbod LP, Bouchelouche K, Sorensen J, Harms HJ, Flyvbjerg A, Tarnow L, Kistorp C, Gustafsson I, Botker HE, Wiggers H. Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. J Nucl Cardiol. 2019 Apr;26(2):585-597. doi: 10.1007/s12350-017-1000-2. Epub 2017 Aug 2.
• Jorsal A, Wiggers H, Holmager P, Nilsson B, Nielsen R, Boesgaard TW, Kumme A, Moller JE, Videbaek L, Kistorp C, Gustafsson I, Tarnow L, Flyvbjerg A. A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study). BMJ Open. 2014 May 20;4(5):e004885. doi: 10.1136/bmjopen-2014-004885.

Drugs

Indications